pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene Europe Limited
Celgene drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 80 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Celgene drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L02) compound in Celgene's portfolio. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: Coagulation factor X.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: 26S proteasome.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: 26S proteasome.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
Systemic hormonal preparations (H02) compound in Celgene's portfolio.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Tubulin.
Antineoplastic and immunomodulating agents (L01) compound in Celgene's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.
US regulatory status: approved. Molecular target: SLAM family member 7.
US regulatory status: approved. Molecular target: T cell surface glycoprotein CD3.
US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP], mitochondrial.
US regulatory status: approved. Molecular target: Androgen receptor.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA topoisomerase II.
Development asset linked to Celgene in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in Celgene's portfolio. Molecular target: Tyrosine-protein kinase JAK2.
US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
Antineoplastic and immunomodulating agents (L01) compound in Celgene's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.
Antineoplastic and immunomodulating agents (L01) compound in Celgene's portfolio. Molecular target: Tumor necrosis factor receptor superfamily member 17.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.
Antineoplastic and immunomodulating agents (L01) compound in Celgene's portfolio. Molecular target: 26S proteasome.
US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
Antineoplastic and immunomodulating agents (L01) compound in Celgene's portfolio. Molecular target: B-lymphocyte antigen CD19.
Blood and blood forming organs (B03) compound in Celgene's portfolio. Molecular target: Transforming growth factor beta.
US regulatory status: approved. Molecular target: Transforming growth factor beta.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 5.
US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 1.
US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
US regulatory status: approved.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.
Development asset linked to Celgene in public FDA and regional records.